Please select the option that best describes you:
When would you consider GLP-1 receptor agonists for IIH in patients at a healthy weight and BMI?
E.g., had a successful weight loss attempt and BMI is <25.
Answer from: at Academic Institution
Randomized clinical trial data demonstrate that exenatide (exendin-4), a GLP-1 receptor agonist, reduces ICP in women with active IIH, with reductions of approximately 5–6 cm water of CSF and no serious side effects; this result is both statistically and clinically significant. This pressure-l...
Sign In or Register to read more
Answer from: at Academic Institution
I would consider it if insurance would cover it, and if one has failed the first-line treatment options with acetazolamide, topiramate, and potentially a surgical evaluation. If someone is quickly losing vision/papilledema not improving despite medical management with acetazolamide or topiramate, I ...